Octreotide oral - Chiasma

Drug Profile

Octreotide oral - Chiasma

Alternative Names: Chiasma Investigational Product 1; CHIP-1; Mycapssa; Octreolin; Octreotide acetate - Chiasma; Oral Octreotide; RG3806

Latest Information Update: 12 Nov 2016

Price : $50

At a glance

  • Originator Chiasma
  • Class Antineoplastics; Antisecretories; Cyclic peptides; Indoles; Somatostatins
  • Mechanism of Action Growth hormone releasing factor antagonists; Somatostatin receptor agonists
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    Yes - Acromegaly
  • On Fast track

    Fast track status is assigned by the US FDA so therapies with the potential to address unmet needs can move faster through development.

    No
  • New Molecular Entity No

Highest Development Phases

  • Preregistration Acromegaly
  • Discontinued Portal hypertension

Most Recent Events

  • 01 Feb 2016 Chiasma initiates a phase III trial for Acromegaly in USA (NCT02685709)
  • 08 Jan 2016 Chiasma completes a phase III trial in Acromegaly in Germany, Hungary, Slovenia and Poland (PO) (EudraCT2015-001292-51)
  • 14 Oct 2015 Discontinued - Phase-II for Portal hypertension in Spain (PO) before October 2015
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top